Fail-safe medical technology tube connector for infusion, transfusion and dialysis.

Important results from the project

The project goal was to manufacture, test and demonstrate a first series of prototypes of our product. The prototypes have been manufactured and its key functions tested in a laboratory setting. All results have been documented to be a part of the technical file before future CE-mark process and to be used as basis for the design of the next series of prototypes. The process for IP protection is ongoing, which is currently preventing us from demonstrating our design to users and customers. Awaiting IP protection, we strive to increase our pool of user and customer contacts in other ways.

Expected long term effects

The results from our testing of key functions are very positive. Smaller design adjustments are needed, they will however not affect our planned updated IPR protection strategy or road to market. E.g., we will change one of the two materials constituting the product. Initial tests of the new material are promising. Awaiting being able to demonstrate the product to users and potential customers, we have made a study of the need behind our innovation. The study was performed with the aid of nurses/users from Örebro University Hospital, the results confirmed the magnitude of the need.

Approach and implementation

Using the Stanford biodesign process, we are constantly working on validating and quantifying the need our invention address. To reach success, it is important for our need to be well known on the market. Here we can use our study as proof. Early in the project, we evaluated the technical solution with regards to ’transfer to production’. This resulted in improvements regarding design and choice of material making the product easier and cheaper to produce both in small and large scale. The design alterations were reviewed by our patent attorney who saw the need for additional IP protection.